Scrying Biotech
Contributor since: 2012
Company: Scrying biotech
Latest Articles
The Sarepta 12
Sarepta Will Take Flight When BioMarin Taxis Off The Runway
Amarin: Anatomy Of An Xmas Cash Biotech Play
Why I've Changed My Thinking About Trevena
Zephyrs Of Hope Within The Zafgen Storm
The Inextricable Link Between Politics And Biopharma Investing
Trevena's CEO Maxine Gowen Is In An Enviable Position
Where NovaBay Is Concerned Push Has Already Come To Shove
Ocata Therapeutics: Are You Watching A Bluebird Go By?
Trevena's GPCR Biased Ligand Technology Could Become The World's Most Prolific Drug Discovery Platform
Trevena Overreacts
3 Promising Biotechs Hobbled By First-Impression Issues
Is A Synergy Pharmaceuticals Buyout Already In Place?
2 Trepidatious Travails Tormenting Trevena's Tried And True
How To Make Money In Small To Nano-Cap Biotech
Synergy Longs Now Have The Upper Hand
NovaBay: How To Play The Wobble In The Paradigm Shift
Synergy Shares Climb After Manipulation Arrests
The Paulson Tug Pushes Synergy Out To Sea
Amarin's Smart 1st Amendment Strategy
NovaBay Pharmaceuticals Seeks To Change The Paradigm Of Eye Care From Practitioner To Patient
Amarin's Constellation Of Possibilities Defy The Fall Of Night
Synergy Pharmaceuticals: Don't Be An April Fool
Trevena's Q4 2014 Results Conference Call - What We Learned
Nektar-102 Will Be An Approved Treatment In Metastatic Breast Cancer
Trevena Inc: Profitable To You And Disruptive To Everyone Else
Where Celldex Is Concerned, Patience Will Be Required
Prospective New Investors Have To Wake Up To See Amarin Now
Nektar CEO Howard Robin Walks Along His Own Path
CellDex Leaves Them All Behind
Seattle Genetics: Zen And Resolve
What The Chances Are Of BEACON's Success And What That Will Mean To Nektar